Clinical trial
Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With…
NCT00376181 · Takeda, Industry · Terminated
Key facts
| NCT number | NCT00376181 |
|---|---|
| Title | Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus |
| Official title | A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Determine the Efficacy, Safety, and Tolerability of AD-4833-536 in the Treatment of Subjects With Type 2 Diabetes |
| Lead sponsor | Takeda, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | Pioglitazone and Azilsartan, Pioglitazone |
| Enrollment | 96 |
| Start date | Jun 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Sep 14, 2006 |
| Last update posted | Jun 22, 2010 |
| Countries | Argentina, Chile, Mexico, Peru, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: